Durable remissions with Ipilimumab in pretreated metastatic malignant melanoma (MMM) patients (pts): Results of a South African Expanded Access Program (EAP).

Abstract

e20112 Background: This retrospective analysis reports data on demographics and outcomes of an ipilimumab South African EAP. Ipilimumab was given at a dose of 3 mg/kg intravenously every 3 weeks fo...